Hemolytic and antimalarial effects of tight-binding glyoxalase 1 inhibitors on the host-parasite unit of erythrocytes infected with Plasmodium falciparum  by Wezena, Cletus A. et al.
Redox Biology 8 (2016) 348–353Contents lists available at ScienceDirectRedox Biologyhttp://d
2213-23
Abbre
glyoxala
glyoxal;
n Corr
Neuenh
E-m
1 Thjournal homepage: www.elsevier.com/locate/redoxResearch paperHemolytic and antimalarial effects of tight-binding glyoxalase 1
inhibitors on the host-parasite unit of erythrocytes infected with
Plasmodium falciparum
Cletus A. Wezena a,1, Miriam Urscher a,1, Robert Vince b, Swati S. More b, Marcel Deponte a,n
a Department of Parasitology, Ruprecht-Karls University, D-69120 Heidelberg, Germany
b Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN 55455, USAa r t i c l e i n f o
Article history:
Received 8 February 2016
Accepted 22 February 2016
Available online 2 March 2016
Keywords:
Glyoxalase
Inhibitor
Redox
Pharmacokinetics
Erythrocyte
Malariax.doi.org/10.1016/j.redox.2016.02.006
17/& 2016 The Authors. Published by Elsevier
viations: AGEs, advanced glycation end produ
se 2; GSH, reduced glutathione; GSSG, glutat
Pf, Plasmodium falciparum
espondence to: Department of Parasitology, R
eimer Feld 324, D-69120 Heidelberg, German
ail address: marcel.deponte@gmx.de (M. Depo
ese authors contributed equally to this worka b s t r a c t
Glyoxalases prevent the formation of advanced glycation end products by converting glycolysis-derived
methylglyoxal to D-lactate with the help of glutathione. Vander Jagt and colleagues previously showed
that erythrocytes release about thirty times more D-lactate after infection with the human malaria
parasite Plasmodium falciparum. Functional glyoxalases in the host-parasite unit might therefore be
crucial for parasite survival. Here, we determined the antimalarial and hemolytic activity of two tight-
binding glyoxalase inhibitors using infected and uninfected erythrocytes. In addition, we synthesized and
analyzed a set of diester derivates of both tight-binding inhibitors resulting in up to threefold lower IC50
values and an altered methemoglobin formation and hemolytic activity depending on the type of ester.
Inhibitor treatments of uninfected erythrocytes revealed an extremely slow inactivation of the host cell
glyoxalase, irrespective of inhibitor modiﬁcations, and a potential dispensability of the host cell enzyme
for parasite survival. Our study highlights the beneﬁts and drawbacks of different esteriﬁcations of
glutathione-derived inhibitors and demonstrates the suitability of glyoxalase inhibitors as a tool for
deciphering the relevance and mode of action of different glyoxalase systems in a host-parasite unit.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The glyoxalase system is considered to be an ancient metabolic
adaptation for the efﬁcient conversion of reactive electrophilic
2-oxoaldehydes to 2-hydroxycarboxylic acids [1]. The system
consists of reduced glutathione (GSH) and two enzymes, the iso-
merase glyoxalase 1 (Glo1) and the thioesterase glyoxalase 2
(Glo2). Even though there are organelles and organisms with in-
sular glyoxalases pointing to alternative functions [1–3], Glo1 and
Glo2 usually act together, for example, to catalyze the formation of
D-lactate from glucose-derived methylglyoxal (MG) [1–5]. The
glyoxalase system in humans prevents the accumulation of MG
and of MG-derived advanced glycation end products (AGEs) with
implications for numerous pathophysiological conditions includ-
ing diabetes and cancer [6–9]. Inhibition of Glo1 is thereforeB.V. This is an open access article u
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.supposed to be an elegant strategy to target cancer cells with high
glycolytic ﬂuxes that necessitate a potent MG removal system
[7,10,11]. An inhibition of pathogen glyoxalases might likewise
result in the accumulation of harmful MG and AGEs in bacteria and
parasites with high glycolytic ﬂuxes [2,3,12–15]. Moreover, the
diverse glyoxalase systems and MG removal strategies of parasitic
protists are not only potential drug targets but are also suited for
the identiﬁcation of alternative glyoxalase functions and me-
chanisms [1–3,15–19].
Two D-lactate producing glyoxalase systems are found in the
host-parasite unit of erythrocytes that are infected with the hu-
man malaria parasite Plasmodium falciparum, one in the ery-
throcyte and one in the parasite cytosol [2,12,19]. The apicoplast of
P. falciparum furthermore harbors a functional Glo2-isoform and a
highly mutated Glo1-like protein that is inactive in standard en-
zymatic assays [2,19,20]. A methylglyoxal reductase activity was
found to be negligible in the host-parasite unit and infected ery-
throcytes were shown to release about thirty times more D-lactate
[12]. Cytosolic PfGlo1 from P. falciparum has been thoroughly
analyzed in vitro. In contrast to its homodimeric human homo-
logue, monomeric PfGlo1 has two different, allosterically coupled
active sites [2,16,19,21]. Both active sites have deviating substratender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Structures of Glo1 inhibitors employed in this study. The hydroxamic acid
moiety mimics the transition state and interacts with the metal center of Glo1.
Abbreviations used for esteriﬁcations are tBu (tert butyl), Me (methyl), Et (ethyl),
cyp (cyclopentyl).
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glutathione-derived inhibitors [21]. Glutathione-derived Glo1
transition-state analogues, termed compound 1 and 2 (Fig. 1),
were previously shown to act as glyoxalase-speciﬁc, non-
competitive tight-binding inhibitors with nanomolar Kiapp values
for recombinant PfGlo1 [21]. Here, we tested the antimalarial ac-
tivity and toxicity of these inhibitors as well as a set of novel ester
derivates in P. falciparum cell culture and on uninfected human
erythrocytes. In addition, we used the inhibitors as a chemical tool
to address the relevance of functional human Glo1 for parasite
survival.2. Materials and methods
2.1. Chemicals
Compounds 1 and 2 were synthesized as previously described
[22]. The synthesis and validation of the ester derivates 3–7 is
described in the Supplementary materials and methods including
Scheme S1. GSH, S-D-lactoylglutathione, MG, and DMSO were ob-
tained from Sigma-Aldrich (Taufkirchen, Germany).
2.2. Growth inhibition assays and hemolysis
Direct growth inhibition of P. falciparum blood stage parasites
was analyzed for strain 3D7 that was cultured according to stan-
dard protocols [23] at 37 °C, 5% CO2, 5% O2, 90% N2 and 80% hu-
midity in RPMI medium containing 0.45% (w/v) Albumax II,
0.2 mM hypoxanthine, 2.7 mg/mL gentamicin and human A ery-
throcytes at an hematocrit of 1.5–3.5%. Synchronization was car-
ried out using the sorbitol method [24]. Inhibition of parasite
growth was determined from three independent experiments by
counting Giemsa-stained blood smears. Compounds 1–7 (50 or
25 mM stock solutions in DMSO) were diluted stepwise in culture
medium in 48-well plates. Afterwards, either asynchronous para-
site cultures or synchronized ring stage parasite cultures were
added to the medium at a ﬁnal hematocrit of 1.5% and an initial
parasitemia of 0.25%. The highest ﬁnal concentration of DMSO in
the cultures was 0.8%. Parasites were grown for 48 h before pre-
paration of blood smears. About 750–1500 erythrocytes were
counted per Giemsa-stained blood smear and data were analyzed
following the recommendations of the National Institutes of
Health Chemical Genomics Center using the four parameter lo-
gistic model for the determination of IC50 values. As a control,
hemolytic effects of the tight-binding inhibitors on unparasitizederythrocytes were analyzed in parallel. After 48 h, erythrocytes
were counted in a Neubauer chamber and the release of he-
moglobin into the medium was determined spectro-
photometrically at 405 nm.
2.3. Inhibition of the host cell Glo1 activity
Erythrocytes from ﬁve different donors were incubated in
complete RPMI medium in the presence of 10 mM compounds 1–3
and 7 or DMSO as a control. The activities of human Glo1 and Glo2
were measured before the addition of each compound and mon-
itored after the addition for 96 h. Every 24 h, erythrocytes were
centrifuged (5 min, 300 g, room temperature) and a 40 mL aliquot
was removed from the cell pellet. The remaining erythrocytes
were resuspended in the original medium for further incubation,
whereas the 40 ml aliquot was resuspended in 500 mL of cold
phosphate-buffered saline (PBS containing 1.84 mM KH2PO4,
10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4 at 24 °C) and
centrifuged again (5 min, 2000 g, 4 °C). The supernatant was dis-
carded and the erythrocyte aliquot was washed two more times
with PBS to remove traces of extracellular inhibitors. Washed ery-
throcytes were subsequently lysed by resuspension in 200 mL of
ice-cold water until the solution became clear. After centrifugation
(10 min, 20,000 g, 4 °C), the supernatant was stored on ice pend-
ing immediate enzyme assays and hemoglobin measurements.
The hemoglobin content in erythrocyte lysates was determined by
adding 20 mL of lysate to 980 mL of 50 mM Tris/HCl, pH 7.4 at 37 °C
and measuring the absorbance at the isosbestic point at 523 nm.
The concentration was calculated using the formula
[Hb]¼Abs523nm 50 7.12 [mM] or [Hb]¼Abs523nm 16.1 50 7.12
[g/L] [25]. Activities of human Glo1 and Glo2 were determined at
240 nm and 37 °C using a thermostatted Jasco V-550 UV–vis
spectrophotometer according to standard protocols [26,27] with
slight modiﬁcations. Brieﬂy, stock solutions of 100 mM GSH and
100 mM MG were freshly prepared in cold Glo1 assay buffer
(50 mM NaxHyPO4, pH 6.6 at 37 °C) before each experiment and
stored on ice. The hemithioacetal substrate was formed after
mixing 955 mL of pre-warmed Glo1 assay buffer with 20 mL each of
the GSH and MG stock solutions followed by an incubation at 37 °C
for 9.5 min. A baseline was subsequently recorded for 30 s and the
Glo1 assay was started by the addition of 5 mL of erythrocyte ly-
sate. The absorbance was monitored for 1.5 min and the activity
was calculated using ε240 nm¼2.86 mM1 cm1. For human Glo2
measurements, a stock solution of 3 mM S-D-lactoylglutathione
was freshly prepared in cold Glo2 assay buffer (50 mMTris/HCl, pH
7.4 at 37 °C) before each experiment and stored on ice. A baseline
was recorded for 30 s after mixing 890 mL of pre-warmed Glo2
assay buffer with 100 ml of 3 mM S-D-lactoylglutathione. The Glo2
assay was started by the addition of 10 mL of cell lysate, and the
absorbance was monitored for 1.5 min. Human Glo2 activities
were calculated using ε240nm¼3.1 mM1 cm1. All human Glo1
and Glo2 activity measurements were performed in triplicates and
were normalized to the corresponding hemoglobin concentration
of the lysates. Statistical analyses were performed in SigmaPlot
12.5 using the one way ANOVA on ranks method.
2.4. Effect of the host cell Glo1 activity on P. falciparum blood stage
cultures
A potential indirect growth inhibition of P. falciparum blood
stage cultures was determined with erythrocytes that were pre-
treated with compounds 1, 3 and 7 as described above. After 96 h
inhibitor treatment, erythrocytes were washed three times with
complete RPMI medium before adding synchronized schizont
parasites (purity Z98%) that were enriched by magnetic cell se-
paration [28,29] using a VarioMACS™ Separator with CS columns
Fig. 2. IC50 values for synchronous and asynchronous P. falciparum cultures. The inﬂuence of the esteriﬁcations in compounds 6, 3 and 7 on the growth of blood stage
parasites was analyzed in cell culture by counting Giemsa-stained blood smears. The inhibitors had a nearly identical inﬂuence on synchronous or asynchronous cultures
(closed and open circles, respectively) yielding IC50 values of about 30 mM. Data points were averaged from at least two independent experiments.
C.A. Wezena et al. / Redox Biology 8 (2016) 348–353350(Miltenyi Biotec). Parasite growth was averaged from three in-
dependent experiments by counting Giemsa-stained blood
smears. Statistical analyses were performed in SigmaPlot 12.5
using the one way ANOVA on ranks method.3. Results
3.1. Direct growth inhibition of P. falciparum blood stage cultures
Our previous enzymatic studies showed that compounds 1 and
2 inhibit recombinant PfGlo1 at low nanomolar concentrations
[21]. We therefore also examined the effect of these substances on
the growth of P. falciparum blood stage cultures using Giemsa-
stained blood smears. Compounds 1 and 2 inhibited parasite
growth after 48 h with IC50 values around 70 or 90 mM (Table 1).
Because esteriﬁcation of the two carboxyl groups of glutathione-
derived Glo1 inhibitors previously led to more potent agents,
presumably because of an improved cellular uptake [11,13,30–32],
we synthesized the diester derivatives 3–7 depicted in Fig. 1 and
subsequently tested these compounds in cell culture. Methyl or
ethyl esteriﬁcations of compound 1 had no inﬂuence on the IC50
values after 48 h drug treatment (data for compounds 4 and 5 not
shown). In contrast, the cyclopentyl diester of 1 (compound 6) and
the tert-butyl diesters of 1 and 2 (compounds 3 and 7) yielded
two- to threefold decreased IC50 values for blood stage parasites
(Fig. 2, Table 1). The IC50 curves displayed a steep slope with a
well-deﬁned toxic threshold resulting in complete parasite death
at higher inhibitor concentrations. In summary, selected ester-
iﬁcations of compounds 1 and 2 improved their efﬁcacy resulting
in IC50 values for P. falciparum blood stage cultures around 30 mM.
3.2. Evaluation of hemolytic side effects
Next, we assessed the toxicity of the compounds on the host
cell as a control. At high micromolar inhibitor concentrations, the
colour of infected and uninfected erythrocytes turned brownish
(Fig. 3A) which is indicative for methemoglobin formation.Table 1
IC50 values for direct P. falciparum growth inhibition by compounds 1, 2 or its esters.
Inhibitor IC50 (mM)
Compound 1 70a,s
Compound 3 35a,s
Compound 6 30a,s
Compound 2 90a/70s
Compound 7 30a,s
Each compound was tested in at least two different experiments. Except for com-
pound 2, no difference was observed between asynchronous (a) and
synchronous (s) cultures (Fig. 2).Furthermore, a loss of erythrocytes, as determined by cell count-
ing, and the release of hemoglobin, as determined by spectro-
photometry, were observed in a compound- and concentration-
dependent manner (Fig. 3B, C). The hemolytic effect was most
pronounced for 200 mM of compound 6 resulting in cell lysis of
more than 40% of erythrocytes and a 30-fold increase of he-
moglobin release as compared to the other compounds. However,
except for the more toxic cyclopentyl diester compound 6, the
inhibitors had rather moderate toxic side effects on uninfected
erythrocytes at IC50 concentrations for P. falciparum around 30 mM.
In summary, the tight-binding Glo1 inhibitors led to methe-
moglobin formation and hemolysis at high micromolar con-
centrations whereas concentrations around the IC50 values ap-
peared to be safe for the host cell except for compound 6.
3.3. Effect of the host cell Glo1 activity on P. falciparum blood stage
cultures
To date there are no glyoxalase knockout erythrocytes avail-
able. We therefore used our inhibitors as a molecular tool to
analyze the relevance of functional human Glo1 on parasite
growth (Fig. 4A). The effect of the inhibitors on the host cell Glo1
activity was ﬁrst determined in a time course experiment with
uninfected erythrocytes and 10 mM of each compound to exclude
hemolysis as a confounding parameter. Activities of human Glo1
and Glo2 in DMSO controls from ﬁve different blood donors were
0.15370.038 and 0.05570.016 U/mg hemoglobin, respectively.
These values are in good agreement with previously published
activities [33]. Compound 1 acted quite slowly on uninfected ery-
throcytes resulting in a three-fold reduction of the Glo1 activity
after 96 h incubation (Fig. 4B). Esteriﬁcation of the carboxylate
groups in compounds 3 and 7 did not further improve the phar-
macokinetics and inhibitor potency after 96 h as compared to
compounds 1 and 2 (Fig. 4C, left panel). Surprisingly, treatment of
erythrocytes with compounds 2 and 7 for 96 h also appeared to
slightly increase the activity of human Glo2 (Fig. 4C, right panel).
Infection of erythrocytes after 96 h of inhibitor pre-treatment ac-
cording to the scheme in Fig. 4A had no effect on parasite growth
(Fig. 4D). In summary, the activity of human Glo1 appears to be
dispensable for the development of P. falciparum in cell culture.4. Discussion
What can we learn from our studies on glutathione-derived
inhibitors? Regarding the activity of compounds 1 and 2 on P.
falciparum blood stage parasites, the IC50 values around 70 mM
were three to four orders of magnitude higher than the IC50 values
with recombinant enzyme [21]. A plausible cause might be an
inefﬁcient cellular uptake of the inhibitors. According to previous
studies [11,13,30–32], efﬁcient delivery of glutathione-derived
Fig. 3. Hemolysis of uninfected erythrocytes. (A) Erythrocyte cultures that were
treated for 48 h with inhibitor concentrations Z100 mM turned brownish. (B) High
inhibitor concentrations led to hemolysis as revealed by counting erythrocytes in a
Neubauer chamber and normalizing the counts against untreated erythrocytes.
(C) The supernatants of the erythrocyte cultures depicted in panel B were analyzed
photometrically for hemoglobin release at 405 nm. The absorbance increased with
increasing inhibitor concentration for all compounds tested. The indicated absor-
bances reﬂect calculated values considering a dilution factor. Data points were
averaged from triplicate measurements of at least two independent experiments.
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compound. Esteriﬁcation of the glutathione moiety reduces its
polarity and is supposed to facilitate the uptake of the drugs. We
were therefore surprised that, under the chosen assay conditions
in Fig. 4, esters of compounds 1 and 2 did not result in a faster or
more potent inhibition of human Glo1 in uninfected erythrocytes.
Furthermore, in contrast to the reported effect of the ethyl diester
of S-p-bromobenzylglutathione on parasite growth [13], weobserved no improvement of the IC50 values when P. falciparum
cultures were treated with ethyl (or methyl) diesters of compound
1. However, modiﬁcation of compound 1 by cyclopentyl esters led
to a more than twofold decrease of the IC50 value in accordance
with previous studies on the inhibition of human leukemia 60
cells by the cyclopentyl diester of S-p-bromobenzylglutathione
[11]. Another interesting observation was that the tert-butyl di-
esters of compounds 1 and 2 yielded similar IC50 values as the
cyclopentyl diester but were far less toxic for the host cell. Hence,
the type of ester can actually impact the growth inhibition of
malaria parasites and the toxicity for the host cell in different
ways. The slightly lower IC50 value for compound 7 in comparison
to compound 3 might be explained by an absent turnover of
compound 7 by γ-glutamyltranspetidase [22]. In summary, the
polarity and type of ester of glutathione-derived Glo1 inhibitors
are both important. Bulky esters yielded lower IC50 values ac-
companied by an increased hemolytic toxicity, which was much
higher for the cyclopentyl than for the tert-butyl diester of com-
pound 1. Other factors, such as the drastically increased host cell
permeability upon infection, as reviewed in [34] and [35], can also
have signiﬁcant effects on the potency of Glo1 inhibitors and are
difﬁcult to predict.
What is the mode of action of the tested inhibitors and how can
they lead to methemoglobin formation? A physiologically relevant
link between Glo1 activity and redox imbalances in vivo was re-
cently suggested for diabetic rats that produced less reactive
oxygen species upon overexpression of GLO1 [36]. Using a set of
recombinant proteins, we previously showed that compounds 1
and 2 speciﬁcally act on the glyoxalase system and not on other
glutathione-utilizing enzymes such as glutathione reductase or
glutaredoxin [21]. An interesting question is therefore how me-
themoglobin formation upon inhibitor treatment of uninfected
erythrocytes could be linked to glyoxalase inhibition. Two models
appear to be plausible (Fig. 5). (i) While 2-oxoaldehyde formation
continues upon glyoxalase inhibition, more and more GSH reacts
with these electrophiles, and the pool of available GSH might get
depleted. As a consequence, the ratio [GSH]2:[GSSG] (as derived
from the Nernst equation) decreases and oxidizing metabolites
accumulate over time resulting in an increased methemoglobin
concentration (Fig. 5A). (ii) Alternatively, MG and other 2-oxo-
aldehydes might inactivate selected antioxidant enzymes by
modifying their essential active site (cysteine) residues (Fig. 5B).
Since erythrocytes lack de novo protein biosynthesis, they should
be particularly susceptible to enzyme inactivation resulting in re-
dox imbalances. Such considerations are not only important for
deciphering mechanistic links between glyoxalase and redox me-
tabolic pathways but also regarding the potential necessity to
generate non-toxic, parasite-speciﬁc glyoxalase inhibitors. For ex-
ample, in analogy to the malaria protection hypothesis for people
with glucose-6-phosphate dehydrogenase deﬁciency [37], a
moderate effect of inhibitors on the erythrocyte glyoxalase system
might even be beneﬁcial because the parasite has to face a more
hostile environment [2] and drug resistances are less likely to
arise. Furthermore, if P. falciparum imports human Glo1 to cope
with elevated MG concentrations (similar to peroxide detoxiﬁca-
tion by imported human peroxiredoxin 2 [38]), inhibition of the
host cell enzyme might be a prerequisite for killing the parasite.
Our data on the (ir)relevance of human Glo1 for parasite survival
(Fig. 4) supports neither of both hypotheses, although we cannot
fully exclude that the residual host cell Glo1 activity was sufﬁcient
to compensate a growth phenotype.
In conclusion, derivatives of compounds 1 and 2 have moderate
antimalarial activities. They can also alter the redox milieu of
human erythrocytes and could serve as an interesting tool for
deciphering the molecular mechanism of how the glyoxalase
system exerts its physiological protective function. The activity of
Fig. 4. Effect of the host cell Glo1 activity on P. falciparum blood stage cultures. (A) Experimental design to analyse the relevance of human Glo1 for parasite development.
Uninfected erythrocytes in complete RPMI medium were incubated with compounds 1–3, 7 or DMSO and subsequently infected in the absence of the tight-binding
inhibitors by adding puriﬁed schizont stage parasites. (B) Representative time course measurement of human Glo1 activity upon treatment of uninfected erythrocytes with
10 mM of compound 1. (C) Time-dependent effect of 10 mM of compounds 1–3 and 7 on human Glo1 and Glo2 activities in uninfected erythrocytes. Stars indicate a p-value
o0.05; n.s., not signiﬁcant. (D) Growth curve analysis of P. falciparum parasites according to panel A. Erythrocytes were pre-treated for 96 h with 10 mM of compounds 1, 3
and 7, washed, and infected with puriﬁed parasites (day 0). All data points in panels B-D were averaged from 3–5 independent experiments with different blood donors.
Fig. 5. Potential mechanistic links between glyoxalase inhibition and altered redox
states resulting in methemoglobin formation. (A) Accumulation of the hemi-
thioacetal (HTA) between glutathione and MG might result in GSH depletion and a
subsequent increase of the steady-state concentrations of oxidizing metabolites.
(B) Increased steady-state concentrations of MG or other 2-oxoaldehydes might
alternatively inactivate selected oxidoreductases.
C.A. Wezena et al. / Redox Biology 8 (2016) 348–353352human Glo1 does not seem to play a major role for the develop-
ment of P. falciparum in cell culture. Regarding the esteriﬁcation
and optimization of Glo1 inhibitors, a balance between inhibitor
activity, speciﬁcity, selectivity and toxicity has to be determined
empirically. A future strategy could comprise the synthesis of
conjugates between compounds 1 or 2 and existing antimalarial
drugs. This might further facilitate the uptake into parasitized
erythrocytes and may also exhibit a synergistic effect, as has been
described for a double-drug glutathione reductase inhibitor [39].Acknowledgements
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